The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo

[1]  T. Cikač,et al.  HAND-FOOT-AND-MOUTH-DISEASE (HFMD) , 2016 .

[2]  Cécile Viboud,et al.  Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. , 2014, The Lancet. Infectious diseases.

[3]  P. Tien,et al.  Cell Surface Vimentin Is an Attachment Receptor for Enterovirus 71 , 2014, Journal of Virology.

[4]  J. Héraud,et al.  Molecular Comparison and Evolutionary Analyses of VP1 Nucleotide Sequences of New African Human Enterovirus 71 Isolates Reveal a Wide Genetic Diversity , 2014, PloS one.

[5]  M. Rossmann,et al.  Structure of human enterovirus 71 in complex with a capsid-binding inhibitor , 2013, Proceedings of the National Academy of Sciences.

[6]  Xiaoling Zhang,et al.  Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. , 2013, Antiviral research.

[7]  Hongling Zhao,et al.  Study of the Integrated Immune Response Induced by an Inactivated EV71 Vaccine , 2013, PloS one.

[8]  K. Fujii,et al.  Functional Comparison of SCARB2 and PSGL1 as Receptors for Enterovirus 71 , 2013, Journal of Virology.

[9]  R. Altmeyer,et al.  Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study , 2013, Emerging Microbes & Infections.

[10]  J. Farrar,et al.  Enterovirus 71–associated Hand, Foot, and Mouth Disease, Southern Vietnam, 2011 , 2012, Emerging infectious diseases.

[11]  I. Sam,et al.  Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor , 2012, Journal of Virology.

[12]  C. Poh,et al.  In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. , 2012, Virus research.

[13]  G. Leroux-Roels,et al.  Blocking HCV entry as potential antiviral therapy , 2012 .

[14]  A. Debnath,et al.  Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. , 2012, Journal of medicinal chemistry.

[15]  M. Grever,et al.  Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes , 2012, Cancer Chemotherapy and Pharmacology.

[16]  Shan Xu,et al.  Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  F. Zhou,et al.  In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection , 2012, Archives of Virology.

[18]  Y. Qi,et al.  Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications , 2012, Virology Journal.

[19]  Lianfeng Zhang,et al.  Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication , 2011, Virology Journal.

[20]  Hongling Zhao,et al.  Pathogenesis study of enterovirus 71 infection in rhesus monkeys , 2011, Laboratory Investigation.

[21]  Hualiang Jiang,et al.  Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design , 2011, Journal of Virology.

[22]  B. Blackburn,et al.  SYMPOSIUM ON ANTIMICROBIAL THERAPYAntiparasitic Therapy , 2011 .

[23]  O. Cars,et al.  Protein Binding: Do We Ever Learn? , 2011, Antimicrobial Agents and Chemotherapy.

[24]  Hongling Zhao,et al.  Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. , 2011, Virology.

[25]  T. Solomon,et al.  Clinical features, diagnosis, and management of enterovirus 71 , 2010, The Lancet Neurology.

[26]  Tom Solomon,et al.  Virology, epidemiology, pathogenesis, and control of enterovirus 71. , 2010, The Lancet. Infectious diseases.

[27]  S. Diedrich,et al.  Phylogenetic evidence for a recent spread of two populations of human enterovirus 71 in European countries. , 2010, The Journal of general virology.

[28]  M. Grever,et al.  Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer , 2010, Cancer Chemotherapy and Pharmacology.

[29]  Ching-Chuan Liu,et al.  Enterovirus 71: epidemiology, pathogenesis and management , 2009, Expert review of anti-infective therapy.

[30]  M. Shimojima,et al.  Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71 , 2009, Nature Medicine.

[31]  S. Koike,et al.  Scavenger receptor B2 is a cellular receptor for enterovirus 71 , 2009, Nature Medicine.

[32]  Rong Zhao,et al.  Enterovirus 71 Outbreak in the People's Republic of China in 2008 , 2009, Journal of Clinical Microbiology.

[33]  G. Holloway,et al.  Sialic acid dependence in rotavirus host cell invasion. , 2009, Nature chemical biology.

[34]  E. De Clercq,et al.  Selective inhibitors of picornavirus replication , 2008, Medicinal research reviews.

[35]  T. Wakita,et al.  Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. , 2008, The Journal of general virology.

[36]  T. Haselhorst,et al.  Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. , 2008, Angewandte Chemie.

[37]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[38]  R. Altmeyer.  Virus attachment and entry offer numerous targets for antiviral therapy. , 2004, Current pharmaceutical design.

[39]  N. Nagata,et al.  Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. , 2004, The Journal of general virology.

[40]  P. Chiodini,et al.  Sleeping sickness in brothers in london. , 2004, The Pediatric infectious disease journal.

[41]  N. Nagata,et al.  Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71 , 2002, Journal of medical virology.

[42]  O. Sartor,et al.  Suramin's Development: What Did we Learn? , 2002, Investigational New Drugs.

[43]  C. Panosian,et al.  Human antiprotozoal therapy: past, present, and future , 1995, Clinical microbiology reviews.

[44]  H. Blum,et al.  Suramin prevents duck hepatitis B virus infection in vivo , 1993, Antimicrobial Agents and Chemotherapy.

[45]  G. Hunsmann,et al.  Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. , 1987, The Journal of general virology.

[46]  L. Napier.  Treatment of Kala-Azar , 1925, The Indian medical gazette.

[47]  W. Yorke.  THE TREATMENT OF KALA-AZAR BY “BAYER 205.” , 1923, British medical journal.

[48]  A. Webster,et al.  Pleconaril--an advance in the treatment of enteroviral infection in immuno-compromised patients. , 2005 .

[49]  O. Sartor,et al.  A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response , 1996, Cancer Chemotherapy and Pharmacology.

[50]  H. Scher,et al.  Use of adaptive control with feedback to individualize suramin dosing. , 1992, Cancer research.

[51]  J. Basnuevo,et al.  [Antiparasitic therapy]. , 1953, Revista Kuba de medicina tropical y parasitologia.